Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...
BMS
BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...
BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC
The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application...
BMS Seeks FDA Priority Review for Krazati in Advanced Colorectal Cancer
Bristol Myers Squibb (BMS; NYSE: BMY) has submitted a priority review application to the U.S....
BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a...
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...
Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial
Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...
EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...
BMS’s Abraxane Approved in China for First-Line Metastatic Pancreatic Cancer Treatment
Bristol Myers Squibb (BMS, NYSE: BMY), a leading U.S. pharmaceutical company, has announced that it...
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention...